Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Sep 27, 2024
Trial Information
Current as of June 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help reduce headache pain in patients who have experienced a subarachnoid hemorrhage (SAH), which is bleeding in the area around the brain. Researchers want to see if a procedure called a transnasal sphenopalatine ganglion block (SPG block) can provide better relief from headaches when used alongside standard pain medications. The trial will also look at whether this new treatment can help reduce the need for stronger pain relief medications, like opioids, during the hospital stay and after discharge.
To participate in this study, individuals must be at least 18 years old and have been diagnosed with acute subarachnoid hemorrhage. They should also have a secured aneurysm, which means the source of the bleeding is treated and stable. Participants will be asked to share their pain levels with the healthcare team so that they can assess how well the treatment is working. It’s important to note that potential participants cannot have certain conditions, such as nasal or facial injuries in the past three months, allergies to specific medications, or be unable to provide consent. This trial is currently recruiting participants, and it aims to improve headache management for those affected by SAH.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute subarachnoid hemorrhage
- • Age greater than 18 years
- • Secured aneurysm
- • Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision
- • maker
- • Patient or surrogate decision maker is available to consent
- Exclusion Criteria:
- • Less than 18 years old
- • Unsecured aneurysm
- • Pregnant or lactating
- • Prisoner
- • Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker
- • Nasal or facial trauma or surgery within the last three months
- • Allergy to lidocaine, bupivacaine, or dexamethasone
- • Patient is unable to consent and no available surrogate decision maker
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Trial Officials
Christine Picinich, MS, AGACNP-BC, CCRN
Principal Investigator
University of California, Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported